| Dr Robert E Hood, MD | |
|
22 S Greene St, Baltimore, MD 21201-1544 | |
| (410) 328-5793 | |
| (410) 328-0248 |
| Full Name | Dr Robert E Hood |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 41 Years |
| Location | 22 S Greene St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962449975 | NPI | - | NPPES |
| 1000035855 | Medicaid | DE | |
| 3810011288 | Medicaid | WV | |
| 621999-01 | Other | MD | BLUE CROSS/BLUE SHIELD |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Maryland Medical Center | Baltimore, MD | Hospital |
| University Of Md Medical Center Midtown Campus | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Maryland Physicians P.a. | 2769394808 | 313 |
News Archive
Hearing loss is one of the most common birth defects, with more than 12,000 children in the United States affected each year. Three students in Wichita State University's biomedical engineering program recognized this issue and designed their senior project to create a therapeutic toy to provide early intervention therapy for children with auditory disabilities.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.
A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.
A recent study of 81 cases, published in the Journal of Vertebral Subluxation Research (JVSR), is the first to show that correction of upper neck injuries may reverse the progression of both Multiple Sclerosis (MS) and Parkinson's disease (PD).
› Verified 3 days ago
| Entity Name | University Of Maryland Physicians P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689623175 PECOS PAC ID: 2769394808 Enrollment ID: O20031105000792 |
News Archive
Hearing loss is one of the most common birth defects, with more than 12,000 children in the United States affected each year. Three students in Wichita State University's biomedical engineering program recognized this issue and designed their senior project to create a therapeutic toy to provide early intervention therapy for children with auditory disabilities.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.
A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.
A recent study of 81 cases, published in the Journal of Vertebral Subluxation Research (JVSR), is the first to show that correction of upper neck injuries may reverse the progression of both Multiple Sclerosis (MS) and Parkinson's disease (PD).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert E Hood, MD Po Box 64442, Baltimore, MD 21264-4442 Ph: (410) 328-5793 | Dr Robert E Hood, MD 22 S Greene St, Baltimore, MD 21201-1544 Ph: (410) 328-5793 |
News Archive
Hearing loss is one of the most common birth defects, with more than 12,000 children in the United States affected each year. Three students in Wichita State University's biomedical engineering program recognized this issue and designed their senior project to create a therapeutic toy to provide early intervention therapy for children with auditory disabilities.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.
A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.
A recent study of 81 cases, published in the Journal of Vertebral Subluxation Research (JVSR), is the first to show that correction of upper neck injuries may reverse the progression of both Multiple Sclerosis (MS) and Parkinson's disease (PD).
› Verified 3 days ago
Dr. Leonard Anang Sowah, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |